Skip to main content
Figure 3 | Respiratory Research

Figure 3

From: Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps

Figure 3

Exacerbation rate by study treatment and GINA treatment step at study entry.

BUD/FORM = budesonide/formoterol; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist; SABA = short-acting β2-agonist

BUD/FORM maintenance and reliever therapy vs. higher maintenance dose ICS + SABA, exacerbation rate ratio (95% confidence interval): Step 2, 0.829 (0.570, 1.207); Step 3, 0.431 (0.353, 0.526); Step 4, 0.624 (0.512, 0.761). BUD/FORM maintenance and reliever therapy vs. same maintenance dose ICS/LABA + SABA, exacerbation rate ratio (95% confidence interval): Step 2, 0.583 (0.389, 0.874); Step 3, 0.455 (0.371, 0.558); Step 4, 0.519 (0.434, 0.620). BUD/FORM maintenance and reliever therapy vs. higher maintenance dose ICS/LABA + SABA, exacerbation rate ratio (95% confidence interval): Step 3, 0.795 (0.631, 1.002); Step 4, 0.665 (0.549, 0.807).

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us